Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri(Istituto Oncologico Romagnolo), Andrew Kuykendall(Moffitt Cancer Center), Alessia Tieghi(Azienda Sanitaria Unità Locale di Reggio Emilia), Roberto M. Lemoli(University of Genoa), Luca Tosoni(University of Udine), Daniela Cilloni(Centre de Recherche Jean Pierre Aubert), Chiara Sartor(University of Bologna), Mario Tiribelli(University of Udine), Giulia Benevolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Mirko Farina(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Eloise Beggiato, Monica Bocchia(University of Siena), Emilia Scalzulli(Policlinico Umberto I), Giuseppe A. Palumbo(University of Catania), Elisabetta Abruzzese(St. Eugenio Hospital), Alessandro Isidori, Massimiliano Bonifacio(University of Verona), Giovanni Caocci(University of Cagliari), Gianni Binotto(University of Padua), Erika Morsia(Marche Polytechnic University), Andrea Duminuco(Policlinico Universitario di Catania), Novella Pugliese(University of Naples Federico II), Massimo Breccia(Policlinico Umberto I), Filippo Branzanti(University of Bologna), Alda Strazimiri(University of Verona), Elena Maria Elli(Azienda Ospedaliera San Gerardo), Florian H. Heidel(Medizinische Hochschule Hannover), Francesco Cavazzini(University of Ferrara), Alessandra Dedola(University of Bologna), Fabrizio Pane(Federico II University Hospital), Bruno Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Monica Crugnola(Ospedale di Parma)
Cited by 5
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|PubMed|2006|909
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464